Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab Pilot in Boys with DMD
NCT03936894Phase 2Unknown
- Sponsor
- Children's National Research Institute
- Start
- May 2019
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of canakinumab in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Clinical adverse events at 4 weeks and Laboratory adverse events at 4 weeks. Status: unknown.
02
Drugs
canakinumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03936894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936894.